Stocks
RenovoRx, Inc.RNXT
NASDAQHealthcareBiotechnology$1.27
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted drug delivery platforms for oncology, with its lead candidate in late-stage trials for treating bile duct cancer. Investors track it for its potential to improve chemotherapy efficacy while reducing systemic toxicity.
52W Range: $0.70-$2.59
Congressional Interest in RenovoRx, Inc. (RNXT)
No congressional trades have been disclosed for RenovoRx, Inc. (RNXT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RNXT?
No congressional trades found for this stock.